Strategic partnerships There is active interest in co-development and partnerships for Ampligen and Alferon with major pharma players and academic centers (e.g., Erasmus MC, AstraZeneca collaboration). Leverage to position AIM as a partner for late-stage trials, manufacturing scale-up, and global commercialization.

Clinical expansion Ongoing and planned trials across cancer indications and ME/CFS, plus Japanese Orphan Drug Designations in consideration, indicate multi-region clinical activity and potential for milestone-driven collaborations, licensing, or joint ventures.

Manufacturing readiness Own 30,000-square-foot GMP facility for Ampligen and Alferon provides a manufacturing backstop for partner programs and faster supply for joint Phase 3 trials, presenting opportunities for contracted manufacturing or co-sourcing deals.

Financial runway Revenue in the 10–25M range with ~32M in funding suggests a growing but capital-light profile ideal for milestone-based partnerships, co-investments, or upfronts tied to program advancement and commercialization rights.

Industry visibility Active engagement in high-profile conferences and media coverage around SITC, Marie Curie Symposium, and strategic webinars signals fundraising and collaboration momentum—use these events to secure visibility with potential CROs, sponsors, and investors.